USE OF NIMOTUZUMAB IN THE TREATMENT OF LOCALLY ADVANCED ESOPHAGEAL CANCER IN REAL WORLD

Author(s)

Saumell Y¹, Sánchez L², Cabrera L¹, Cepeda M¹
¹Institute of Molecular immunology, Havana, Cuba, ²Center of Molecular Immunology, Havana, Cuba

Presentation Documents

PCN34--strong-u-saumell-y-u-sup-1-sup-strong-sanchez-l-sup-2-sup-cabrera-l-sup-1-sup-cepeda-m-sup-1-sup-br-sup-1-sup-institute-of-molecular-immunology-havana-cuba-sup-2-sup-center-of-molecular-immunology-havana-cuba

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PCN34

Topic

Clinical Outcomes

Topic Subcategory

Comparative Effectiveness or Efficacy, Relating Intermediate to Long-term Outcomes

Disease

Oncology

Explore Related HEOR by Topic

Clinical Outcomes

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now